Select non–T-cell–engaging therapies with evidence of efficacy following relapse after BCMA-directed therapies
| Agent . | Population/design . | n . | % ORR (sCR, CR); median DOR in months (95% CI); median PFS in months (95% CI) at reported median follow-up . | |||
|---|---|---|---|---|---|---|
| Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC (or mAB) . | BCMA-exposed . | All patients . | ||
| Selinexor (+ various)28 | BCMA-exposed subgroup in the STOMP trial (NCT02343042) —multicenter, open-label, phase 1b/2 study of selinexor in combination with backbone agents | 2 | 1 | 8 | 63.6% (0% ≥ CR); NE (10.6-NE); NE (6-NE) at 14.3 months, with various regimens including XPd, XVd, XKd, XPVd, and XPEd | Various |
| Iberdomide (+ dex)29,42 | BCMA-exposed cohort in CC-220-MM-001 trial (NCT02773030), multicenter, open-label, phase 1b/2 study | 17 | 9 | 13 | 37% (5.3% ≥ CR); 7.5 (3.2-NE); 2.4 (2.1-4.2) at 8.1 months | At RP2D (dose expansion cohort, n = 107): 26% (1% ≥ CR); 4 (2.4-10.5); 3.0 (2.8-3.7) |
| Mezigdomide (+ dex)30 | BCMA-exposed subgroup in CC-92480-MM-001 (NCT03374085), multicenter, open-label phase 1b/2 study | 3 | 8 | 22 | 50% (3.3% ≥ CR); 6.9 (4-NE), 5.4 (2.1-9.4) at 5.8 months | At RP2D (n = 101): 39.6% (5% ≥ CR); 8.3 (5.4-NE); 4.6 (3.2-6.3) at 5.8 months |
| Modakafusp (TAK-573)31 * | BCMA-exposed subgroup in multicenter, open-label phase 1/2 study (NCT03215030) | 15 at RP2D (8 prior CART, prior ADC, and BsAb not specified) | 27% (7% ≥ CR); NR; NR at 5.3 months | At RP2D (n = 30): 43% (10% ≥ CR); 12.5 (1-21); 5.7 (1.2-14) | ||
| Agent . | Population/design . | n . | % ORR (sCR, CR); median DOR in months (95% CI); median PFS in months (95% CI) at reported median follow-up . | |||
|---|---|---|---|---|---|---|
| Prior BCMA CART . | Prior BCMA BsAb . | Prior BCMA ADC (or mAB) . | BCMA-exposed . | All patients . | ||
| Selinexor (+ various)28 | BCMA-exposed subgroup in the STOMP trial (NCT02343042) —multicenter, open-label, phase 1b/2 study of selinexor in combination with backbone agents | 2 | 1 | 8 | 63.6% (0% ≥ CR); NE (10.6-NE); NE (6-NE) at 14.3 months, with various regimens including XPd, XVd, XKd, XPVd, and XPEd | Various |
| Iberdomide (+ dex)29,42 | BCMA-exposed cohort in CC-220-MM-001 trial (NCT02773030), multicenter, open-label, phase 1b/2 study | 17 | 9 | 13 | 37% (5.3% ≥ CR); 7.5 (3.2-NE); 2.4 (2.1-4.2) at 8.1 months | At RP2D (dose expansion cohort, n = 107): 26% (1% ≥ CR); 4 (2.4-10.5); 3.0 (2.8-3.7) |
| Mezigdomide (+ dex)30 | BCMA-exposed subgroup in CC-92480-MM-001 (NCT03374085), multicenter, open-label phase 1b/2 study | 3 | 8 | 22 | 50% (3.3% ≥ CR); 6.9 (4-NE), 5.4 (2.1-9.4) at 5.8 months | At RP2D (n = 101): 39.6% (5% ≥ CR); 8.3 (5.4-NE); 4.6 (3.2-6.3) at 5.8 months |
| Modakafusp (TAK-573)31 * | BCMA-exposed subgroup in multicenter, open-label phase 1/2 study (NCT03215030) | 15 at RP2D (8 prior CART, prior ADC, and BsAb not specified) | 27% (7% ≥ CR); NR; NR at 5.3 months | At RP2D (n = 30): 43% (10% ≥ CR); 12.5 (1-21); 5.7 (1.2-14) | ||
Dex, dexamethasone; XKd, selinexor, carfilzomib, and dexamethasone; XPd, selinexor, pomalidomide, and dexamethasone; XPd-40, selinexor 40 mg, bortezomib, and dexamethasone; XPd-60, selinexor 60 mg, bortezomib, and dexamethasone; XPEd, selinexor, pomalidomide, elotuzumab, and dexamethasone; XPVd, selinexor, pomalidomide, bortezomib, and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.
Updated data presented during ASH 2022 meeting.